Puma Biotechnology, Inc.
- Market Cap (Float-Adj) (Float-adjusted market cap computed by the low-float screener — matches the screener row. May differ from the standard cap (price × all shares outstanding) reported elsewhere.)
- $470.1M
- Price
- $9.24
- % Change (Daily % change from the live per-ticker quote feed.)
- +1.43%
- Volume
- 333.6K
About
Puma Biotechnology, Inc. is a biopharmaceutical company dedicated to the global development and commercialization of treatments aimed at advancing cancer care. Its lead drug candidate, orally administered neratinib (PB272), targets a range of indications. These include patients with early-stage HER2-overexpressed/amplified breast cancer, as well as adults suffering from advanced or metastatic HER2-positive breast cancer when used in combination with capecitabine. Furthermore, PB272 is being explored for solid tumors exhibiting HER2 mutations. The company holds a licensing agreement with Pfizer, Inc. for this drug and has established sub-licensing partnerships with Specialised Therapeutics Asia Pte Ltd., CANbridge BIOMED Limited, Pint Pharma International SA, Knight Therapeutics, Inc., Pierre Fabre Medicament SAS, and Bixink Therapeutics Co., Ltd. Established in 2010, Puma Biotechnology maintains its headquarters in Los Angeles, California.
Quick stats
Shares outstanding50.9M
Computed float37.8M
Float / shares74.4%
Key info
SectorHealthcare
IndustryBiotechnology
CIK (Central Index Key — the unique ID the SEC assigns to every filer. Use it to look up the company's filings on EDGAR.)0001401667
AI Summary
AI-generated1/21
majorbullishearnings
Puma Biotechnology Reports Second Quarter 2026 Financial Results
Puma Biotechnology reported Q2 2026 total revenue of $56.5 million, up from $52.4 million in the prior year, with net income reaching $8.2 million or $0.16 per share.
Management raised full-year 2026 guidance, increasing net product revenue expectations to $205-209 million and total revenue to $224-231 million, citing increased demand for NERLYNX.
The company is now debt-free following the final payment on its 2021 Note Purchase Agreement in May, ending the quarter with $93.9 million in cash and equivalents.
Red flags
- Net cash provided by operating activities dropped to $1.6 million in Q2 2026 from $14.1 million in the prior year
- R&D expenses increased to $18.9 million in Q2 2026 from $15.5 million in Q2 2025